Baxdrostat substantially lowers BP in resistant hypertension

Key takeaways:

Baxdrostat led to substantial BP lowering, with 40% of patients with uncontrolled hypertension reaching BP of less than 130 mm Hg.

Treatment was well-tolerated.

Adding baxdrostat to background antihypertensive therapy led to substantial reductions in seated systolic blood pressure after 12 weeks of treatment among patients with uncontrolled or resistant hypertension.

The results of the phase 3, multinational, double-blind, randomized, placebo-controlled BaxHTN trial of baxdrostat (AstraZeneca), an aldosterone synthase inhibitor, in patients with uncontrolled or resistant hypertension were presented at the European Society of Cardiology Congress and simultaneously published in The New England J ournal of Medicine .

Baxdrostat led to substantial BP lowering, with 40